INSUBCONTINENT EXCLUSIVE:
Nine analysts on an average had expected a profit of Rs 176 crore, according to Refinitiv Eikon data.Biotechnology firm Biocon's quarterly
to Rs 217 crore ($30.54 million) in the third quarter ended December 31, compared with a profit of Rs 91.9 crore a year earlier, the company
said on Thursday.Nine analysts on an average had expected a profit of Rs 176 crore, according to Refinitiv Eikon data.Revenue from
operations grew 45.6 per cent to 15,408 crore, while revenue from its biologics segment more than doubled.($1 = Rs 71.05)
